Business
Karyopharm Expands Board of Directors and Executive Leadership Team and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-- Biotechnology Industry Veteran Chen Schor Appointed to Board of Directors -- -- Stephen Mitchener Named Chief Business Officer, Bringing More than 17 Years
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"-- Biotechnology Industry Veteran Chen Schor Appointed to Board of Directors --\n -- Stephen Mitchener Named Chief Business Officer, Bringing More than 17 Years of Partnering and Corporate Development Experience -\n\n\nNEWTON, Mass., Dec. 1, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointments of Chen Schor, MBA, to its Board of Directors and Stephen Mitchener, PharmD, as Chief Business Officer. Mr. Schor currently serves as President and Chief Executive Officer and a member of the board of directors of Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class therapies for cancer and other diseases. Dr. Mitchener joins Karyopharm from Axcella Healthcare, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health, where he served as Chief Business Officer and Head, Strategic Finance, and spearheaded all commercial, financing, partnering, and corporate development initiatives.\n\"We are thrilled to welcome Chen and Stephen to the Karyopharm team as we continue to execute on our goal of advancing novel treatment options for patients with cancer and other serious diseases,\" said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm. \"Chen is a recognized and skilled leader in the biotechnology industry who has served as President and CEO of multiple, innovative biopharmaceutical companies. Regarding Stephen, his extensive experience leading partnering, marketing, as well as key commercial and strategic initiatives, will be critical to Karyopharm as we look to expand our commercial reach by leveraging our internal capabilities as well as through potential strategic partnerships. We look forward to their contributions as we enter this next chapter of growth for XPOVIO®(selinexor) and our emerging clinical pipeline.\"\n\"I believe Karyopharm is just beginning to achieve its ambitious goal of becoming a leader in the oncology space whose future growth will be driven by the broad therapeutic potential of oral XPOVIO in both hematological malignancies and solid tumors,\" said Mr. Schor. \"I hope that my deep experience in leading several commercial and development-stage biotechnology companies will be beneficial in helping to...